WEKO3
インデックスリンク
アイテム
Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS): Rationale and design
https://doi.org/10.24517/00050645
https://doi.org/10.24517/000506457d403787-ed20-496b-b53a-0a5a3793c939
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
ME-PR-YAMAGISHI-M-1624.pdf (67.5 kB)
|
.png)
|
| Item type | 学術雑誌論文 / Journal Article(1) | |||||||
|---|---|---|---|---|---|---|---|---|
| 公開日 | 2018-05-18 | |||||||
| タイトル | ||||||||
| タイトル | Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS): Rationale and design | |||||||
| 言語 | ||||||||
| 言語 | eng | |||||||
| 資源タイプ | ||||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||||
| 資源タイプ | journal article | |||||||
| ID登録 | ||||||||
| ID登録 | 10.24517/00050645 | |||||||
| ID登録タイプ | JaLC | |||||||
| 著者 |
Miyauchi, Katsumi
× Miyauchi, Katsumi× Kimura, Takeshi× Morimoto, Takeshi× Nakagawa, Yoshihisa× Yamagishi, Masakazu× Ozaki, Yukio× Hiro, Takafumi× Daida, Hiroyuki× Matsuzaki, Masunori |
|||||||
| 著者別表示 |
山岸, 正和
× 山岸, 正和
|
|||||||
| 提供者所属 | ||||||||
| 内容記述タイプ | Other | |||||||
| 内容記述 | 金沢大学医薬保健研究域医学系 | |||||||
| 書誌情報 |
Circulation Journal 巻 70, 号 12, p. 1624-1628, 発行日 2006 |
|||||||
| ISSN | ||||||||
| 収録物識別子タイプ | ISSN | |||||||
| 収録物識別子 | 1346-9843 | |||||||
| NCID | ||||||||
| 識別子タイプ | NCID | |||||||
| 関連識別子 | BA81861067 | |||||||
| DOI | ||||||||
| 関連タイプ | isIdenticalTo | |||||||
| 識別子タイプ | DOI | |||||||
| 関連識別子 | 10.1253/circj.70.1624 | |||||||
| 出版者 | ||||||||
| 出版者 | Japanese Circulation Society = 日本循環器学会 | |||||||
| 抄録 | ||||||||
| 内容記述タイプ | Abstract | |||||||
| 内容記述 | Background: Many trials have shown that 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitors reduce the incidence of cardiovascular events and mortality. One method of decreasing the incidence of cardiovascular events could be to reduce the progression of coronary atherosclerosis, and a recent study found that atorvastatin can cause coronary plaque to regress. To generalize this finding, using conventional HMG-CoA reductase inhibitors at many Japanese centers, randomized trials of pitavastatin and atorvastatin will be conducted with patients with acute coronary syndrome (ACS). Methods and Results: Patients with ACS who have undergone successful percutaneous coronary intervention under intravascular ultrasound guidance will be studied. They will be randomly allocated to pitavastatin or atorvastatin groups and followed up for 8-12 months. The primary endpoint will be the percent change in coronary plaque volume, and secondary endpoints will include absolute changes in coronary plaque volume, serum lipid levels and inflammatory markers. The safety profile will also be evaluated. Conclusions: This study will examine the ability of HMG-CoA reductase inhibitors to regress coronary plaque in Japanese patients with ACS and the findings should help to improve the prognosis of such patients and clarify the involved mechanisms. | |||||||
| 内容記述 | ||||||||
| 内容記述タイプ | Other | |||||||
| 内容記述 | 出版者照会後に全文公開 | |||||||
| 権利 | ||||||||
| 権利情報 | Copyright © Japanese Circulation Society 日本循環器学会 | |||||||
| 著者版フラグ | ||||||||
| 出版タイプ | VoR | |||||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||||
| 関連URI | ||||||||
| 識別子タイプ | URI | |||||||
| 関連識別子 | http://www.j-circ.or.jp/ | |||||||
| 関連名称 | http://www.j-circ.or.jp/ | |||||||
| 関連URI | ||||||||
| 識別子タイプ | URI | |||||||
| 関連識別子 | https://www.jstage.jst.go.jp/browse/circj/-char/en | |||||||
| 関連名称 | https://www.jstage.jst.go.jp/browse/circj/-char/en | |||||||
